Another compound, pyrvinium pamoate, an FDA approved anthelmintic drug, binds non-competitively to a domain of AR that is distinct from ligand binding domain, induces prostate atrophy in vivo [138] and maybe active in the setting of ligand independent AR signaling [139]. Here, AR is linked to Atrophy.